BNS Trials: Lessons in Adherence Monitoring from a Phase Two Study

Speakers
• Esther Hagai, Chief Medical Officer, Clexio Biosciences Ltd
• Morgan Hecker, Clinical Trials Manager, CenExel iResearch Atlanta
• Morad Elmi, Co-Founder & Chief Strategy Officer, Scene Health
• Moderator: Sonya Hunt, XTalks

Top Five Takeaways from the Webinar

1. Observed Adherence Is the Gold Standard—But Needs Scale
Directly Observed Therapy (DOT) is the most reliable way to confirm adherence. Scene Health’s video DOT solution offers a scalable, asynchronous alternative that preserves human observation and increases trial reliability.

2. Real-Time Escalations Improve Safety and Data Quality
Scene’s nurse-led team reviews every video within 12 hours, flagging issues like missed doses, potential abuse, or incorrect use—allowing sites to intervene quickly and improve protocol compliance.

3. Ease of Use Matters—for Both Patients and Sites
The app is simple, intuitive, and doesn’t require new hardware. Patients record and submit their dose in under a minute, and sites get daily reports and rapid support—saving time and reducing friction.

4. Patient Diversity and Tech Access Are Addressed
The app supports 25+ languages, works offline, and includes optional tools like phone stands and pill mats to help low-tech users. Sponsors don’t need to sacrifice diversity for digital innovation.

5. Human Review Outperforms AI Alone
Scene Health uses trained human reviewers to assess every dose video. Unlike fully automated tools, this approach ensures protocol adherence (like dosing timing, pill count, and administration steps) is consistently verified.

Conclusion
In this engaging and practical session, panelists shared how Scene Health supported a controlled-substance phase two trial with strict compliance and safety requirements. From implementation to impact, the discussion revealed why human-led, video-based adherence tools are reshaping the future of clinical trials. Thank you to XTalks, our panelists, and the hundreds who joined live.